Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study

PharmacoEconomics

Volumn 33, Issue 3, 2015, Pages 243-253

  Nosyk, Bohdan ^a,b   Lima, Viviane ^a,c   Colley, Guillaume ^a   Yip, Benita ^a   Hogg, Robert S ^a,b   Montaner, Julio S G ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE REGISTRY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PRIORITY JOURNAL; PROBABILITY; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; ECONOMICS; FACTUAL DATABASE; FOLLOW UP; HEALTH CARE PLANNING; HIV INFECTIONS; HOSPITALIZATION; MIDDLE AGED; REGISTER; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UTILIZATION; VIROLOGY;

ADULT; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; REGISTRIES; TIME FACTORS;

EID: 84925522099     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0229-8     Document Type: Article

References (45)

1. Hogg RS, O’Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
2. Walensky RP, Paltiel AD, Losina E, et al. The survival benefi ts of AIDS treatment in the United States. J Infect Dis. 2006;194:11–9.
3. Bozzette SA, Joce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817–23.
4. Chen RY, Accort NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1003–10.
5. Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Cost-effectiveness of preventing AIDS complications (CEPAC) investigators. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012;26(1):45–56.
6. Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange C, Lima VD, Patterson T, Strathdee S, Williams B, Montaner JSG. Examining the evidence on the causal effect of highly active antiretroviral therapy on transmission of human immunodeficiency virus using the Bradford Hill criteria. AIDS. 2013;27(7):1159–65.
7. Granich R, Gupta S, Suthar A, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo Y-R, McClure C, Montaner J, Hirnschall G, On behalf of the ART in Prevention of HIV and TB Research Writing Group. ART in prevention of HIV and TB: Update on current research efforts. Curr HIV Res. 2011;9:446–69.
8. Walensky RP, Freedberg KA, Weinstein MC, et al. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45:S248–54.
9. Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JSG. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS. 2010;24:1929–35.
10. Bendavid E, Young S, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a South African analysis. Arch Intern Med. 2008;168(17):1910–8.
11. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
12. Gustafson R, Montaner JSG, Sibbald B. Seek and treat to optimize HIV and AIDS prevention. Can Med Assoc J. 2012;184(18):1971.
13. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778–89.
14. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570–85.
15. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr. 2005;39:562–9.
16. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6(3):171–7.
17. Levy A, Johnston K, Annemans L, Tramarin A, Montaner J. The impact of disease stage on direct medical costs of HIV management: a review of the international literature. Pharmacoeconomics. 2010;28(Suppl 1):35–47.
18. Nosyk B, Colley G, Chan K, Yip B, Heath K, Hogg RS, Harrigan PR, Montaner JSG, On behalf of the STOP HIV/AIDS Study Team. Application of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One. 2013;8(1):e54416.
19. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17(3):283–95.
20. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17(3):247–81.
21. Manning WG, Mullahy J. Estimating log models: To transform or not to transform? J Health Econ. 2001;20(4):461–94.
22. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24(3):465–88.
23. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47(7 Suppl 1):S109–14.
24. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.
25. Hogg RS, Heath K, Lima VD, Nosyk B, Kanters S, Wood E, Kerr T, Montaner JS. Disparities in the burden of HIV/AIDS in Canada. PLoS One. 2012;7(11):e47260.
26. Nosyk B, Montaner JSG, Yip B, Lima VD, Hogg RS, on behalf of the STOP HIV/AIDS Study Group. Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996–2011. Med Care. (in press).
27. Burd M. BC Average cost per weighted case (CWC) for CMG + RIW version 2010. BC Ministry of Health. 2010.
28. Canadian Institute for Health Information. Acute Care Grouping Methodologies: From Diagnosis Related Groups to Case Mix Groups to Case Mix Groups Redevelopment. Background paper for the Redevelopment of the Acute Care Inpatietn Grouping Methodology Using ICD-10-CA/CCI Classification Systems. http://secure.cihi.ca/cihiweb/products/Acute_Care_Grouping_Methodologies2004_e.pdf. Accessed 9 Mar 2012.
29. Statistics Canada, Consumer Price Index, Historical Summary (1994–2013) http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ46a-eng.htm. Accessed 30 June 2014.
30. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197–203.
31. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9–15. doi:10.1016/j.drugalcdep.2009.05.021 (Epub 2009 Jul 15).
32. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–54.
33. O’Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334(7):426–31.
34. Lima VD, Zhang W, Yip B, Chan K, Nosyk B, Kanters S, Kozai T, Montaner JSG. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. AIDS. 2012;26(12):1491–500.
35. Park R. Estimation with heteroskedastic error terms. Econometrica. 1966;34:888.
36. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the fifth berkeley symposium on mathematical statistics and probability. 1967. vol. 1, p. 221–33.
37. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817–30.
38. Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010;152(1):18–25.
39. Belotti F, Deb P, Manning WG, Norton EC. Tpm: estimating two-part models. Stata J. 2012;vv(ii):1–13.
40. Walensky R. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. Top HIV Med. 2009;17(4):130–4.
41. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705–15.
42. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–7.
43. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med. 2008;9:721–30.
44. Hoover DR, Graham NM, Chen B, Taylor JM, Phair J, Zhou SY, Munoz A. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr. 1992;5(8):794–802.
45. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002;359:248–52.